URO TODAY: A combination of docetaxel/zoledronic/prednisone in chemotherapy for hormone refractory prostate cancer patients is safe and effective, say Indian researchers. For patients with a Gleason score less than 7, PSA declined more than 50% and those who received more than four cycles had significantly better survival. READ MORE>
Posts Tagged ‘hormone-refractory’
Experiment with chemo combination works for hormone refractory prostate cancer patients
Posted in Chemotherapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, Treatment news, tagged advanced prostate cancer, cancer research, Chemotherapy, docetaxel/zoledronic/prednisone, Gleason score, hormone-refractory, Indian researchers, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, significantly better survival, URO TODAY on October 29, 2009| 1 Comment »
New chemo drugs work well for hormone-resistant prostate cancer patients
Posted in Chemotherapy, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, cancer research, Chemotherapy, docetaxel, estramustine, hormone-refractory, Japanese hormone-refractory prostate cancer patients, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, URO TODAY, well-tolerated treatment on August 20, 2009| Leave a Comment »
URO TODAY: Docetaxel plus estramustine chemotherapy represents an active and well-tolerated treatment for Japanese hormone-refractory prostate cancer patients. READ MORE>
Provenge immunotherapy treatment for advanced prostate cancer emerges well from latest trial, with mild side effects
Posted in Immunotherapy, PROSTATE CANCER, PROSTATE RESEARCH, Provenge, tagged advanced prostate cancer, asthenia (physical weakness), cancer research, cellular immunotherapy, chills, dyspnea (shortness of breath), headache, hormone-refractory, modest toxicity, placebo, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Provenge treatment, PUB MED, pyrexia (fever), Sipuleucel-T, survival benefit, tremor, vomiting, Washington on July 27, 2009| 1 Comment »
JULY 27: PUB MED: A trial involving men with hormone-refractory (advanced) prostate cancer who were treated with Provenge (a cellular immunotherapy product called Sipuleucel-T) had a “survival benefit” and only modest side effects, say the Washington researchers. READ MORE>
The integrated results…demonstrate a survival benefit for patients treated with sipuleucel-T compared with those treated with placebo.
The generally modest toxicity profile, coupled with the survival benefit, suggests a favorable risk-benefit ratio for sipuleucel-T in patients with advanced prostate cancer.
The most common adverse events associated with treatment were chills, pyrexia (fever), headache, asthenia (physical weakness), dyspnea (shortness of breath), vomiting, and tremor.
Prostablog 